Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$20.37 +0.1%	$22.07	$19.00 ▼ $26.58	$2.49B	0.7	1.31 million shs	469,547 shs
CRNX Crinetics Pharmaceuticals	$30.14 +5.8%	$30.42	$24.10 ▼ $62.53	$2.84B	0.33	944,453 shs	630,867 shs
EXAI Exscientia	$4.84	$4.97	$3.80 ▼ $6.49	$632.93M	0.83	713,050 shs	N/A
GMTX Gemini Therapeutics	$59.03 +0.8%	$55.23	$1.16 ▼ $14.10	$2.56B	-0.12	189,291 shs	369,887 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	+3.35%	-8.46%	-6.74%	-13.08%	+5.39%
CRNX Crinetics Pharmaceuticals	+4.02%	-2.60%	-10.80%	-8.98%	-42.55%
EXAI Exscientia	0.00%	0.00%	0.00%	0.00%	-0.41%
GMTX Gemini Therapeutics	+0.97%	-2.01%	+2.95%	+26.41%	+30.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPRX Catalyst Pharmaceuticals	4.885 of 5 stars	3.6	1.0	0.0	3.9	3.2	3.3	3.8
CRNX Crinetics Pharmaceuticals	3.3951 of 5 stars	3.4	0.0	0.0	3.7	2.2	2.5	0.0
EXAI Exscientia	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPRX Catalyst Pharmaceuticals	3.29	Buy	$33.20	63.02% Upside
CRNX Crinetics Pharmaceuticals	2.78	Moderate Buy	$68.86	128.47% Upside
EXAI Exscientia	0.00	N/A	N/A	N/A
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest EXAI, CRNX, GMTX, and CPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	CRNX Crinetics Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$90.00 ➝ $86.00
7/10/2025	CRNX Crinetics Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$36.00
6/27/2025	CRNX Crinetics Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/5/2025	CPRX Catalyst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPRX Catalyst Pharmaceuticals	$558.50M	4.46	$2.53 per share	8.04	$6.99 per share	2.91
CRNX Crinetics Pharmaceuticals	$1.04M	2,729.32	N/A	N/A	$12.44 per share	2.42
EXAI Exscientia	$25.60M	24.72	N/A	N/A	$2.54 per share	1.91
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPRX Catalyst Pharmaceuticals	$163.89M	$1.65	12.33	9.56	0.80	37.36%	40.78%	35.36%	N/A
CRNX Crinetics Pharmaceuticals	-$298.41M	-$4.11	N/A	N/A	N/A	N/A	-32.28%	-29.45%	N/A
EXAI Exscientia	-$181.56M	-$1.51	N/A	N/A	N/A	-882.09%	-49.10%	-33.13%	N/A
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A

Latest EXAI, CRNX, GMTX, and CPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	CRNX Crinetics Pharmaceuticals	-$1.13	-$1.23	-$0.10	-$1.23	$0.52 million	$1.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EXAI Exscientia	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPRX Catalyst Pharmaceuticals	N/A	6.71	6.55
CRNX Crinetics Pharmaceuticals	N/A	17.80	17.80
EXAI Exscientia	0.06	4.54	4.54
GMTX Gemini Therapeutics	N/A	71.49	71.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPRX Catalyst Pharmaceuticals	79.22%
CRNX Crinetics Pharmaceuticals	98.51%
EXAI Exscientia	41.58%
GMTX Gemini Therapeutics	75.42%

Insider Ownership

Company	Insider Ownership
CPRX Catalyst Pharmaceuticals	10.40%
CRNX Crinetics Pharmaceuticals	6.00%
EXAI Exscientia	16.40%
GMTX Gemini Therapeutics	12.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPRX Catalyst Pharmaceuticals	80	122.39 million	109.66 million	Optionable
CRNX Crinetics Pharmaceuticals	210	94.18 million	88.53 million	Optionable
EXAI Exscientia	280	130.77 million	109.32 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable

EXAI, CRNX, GMTX, and CPRX Headlines

Recent News About These Companies

Gemini Therapeutics (NASDAQ:GMTX) Stock Price Up 1.4% - Should You Buy?

August 6, 2025 | marketbeat.com

Gemini Therapeutics (NASDAQ:GMTX) Stock Price Down 1.9% - Should You Sell?

July 15, 2025 | marketbeat.com

What Is Gemini? Everything You Should Know About Google's AI Tool

October 17, 2024 | cnet.com

Google Gemini could soon get a lot more useful on your phone

July 31, 2024 | androidpolice.comA

Gemini Review 2024: Is This Crypto Exchange a Gem for Your Investments?

July 22, 2024 | businessinsider.com

ChatGPT vs. Microsoft Copilot vs. Gemini: Which is the best AI chatbot?

May 23, 2024 | zdnet.comZ

Gemini Monthly Horoscope: May 2024

May 2, 2024 | pedestrian.tvP

Google's Gemini AI Will Work On Your Pixel 2 XL—Android 10, 11 Devices Now Supported

April 28, 2024 | techtimes.comT

Comparing ChatGPT 3.5, Microsoft Bing, and Google Gemini in diagnosing cases of neuro-ophthalmology

April 17, 2024 | ophthalmologytimes.comO

Google's public release of Gemini 1.5 should build trust, Deutsche Bank says

April 17, 2024 | seekingalpha.com

Google takes down Gemini AI image generator. Here’s what you need to know.

February 26, 2024 | washingtonpost.com

‘White privilege is f–king real’: Google Gemini product lead’s old tweets allegedly resurface amid ‘woke’ AI image fiasco

February 26, 2024 | nypost.comN

Google Gemini: Everything you need to know about Google's Answer to ChatGPT – Updated December 2023

December 9, 2023 | androidheadlines.comA

Gemini Review 2023: Pros, Cons and How It Compares

November 16, 2023 | nerdwallet.comN

Yesterday's Gemini Horoscope

October 5, 2023 | yourtango.comY

Gemini Tarot Horoscopes: October 2023

October 3, 2023 | glamour.comG

Yearly Gemini Tarot Card Reading

August 28, 2023 | yourtango.comY

Move over Bard, Google's next big AI product is coming this fall

August 19, 2023 | androidauthority.comA

Radar In Space: The Gemini Rendezvous Radar

July 27, 2023 | hackaday.comH

Sun Transit in Gemini- The twins love the Sun’s visit

July 13, 2023 | prokerala.comP

Sun Transit in Gemini: Sun with Dual energies?

July 5, 2023 | prokerala.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXAI, CRNX, GMTX, and CPRX Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

$20.36 +0.03 (+0.12%)

As of 03:12 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Crinetics Pharmaceuticals NASDAQ:CRNX

$30.14 +1.66 (+5.83%)

As of 03:11 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Exscientia NASDAQ:EXAI

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Gemini Therapeutics NASDAQ:GMTX

$59.03 +0.44 (+0.75%)

As of 08/12/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time